The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs - PubMed (original) (raw)
Review
. 2017 May;49(2):158-196.
doi: 10.1080/03602532.2017.1316285. Epub 2017 Apr 25.
Affiliations
- PMID: 28393622
- DOI: 10.1080/03602532.2017.1316285
Free article
Review
The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs
Ivanna Hrynchak et al. Drug Metab Rev. 2017 May.
Free article
Abstract
Anticancer drugs are presently guarantying more survivors as a result of more powerful drugs or combinations of drugs used in therapy. Thus, it has become more crucial to study and overcome the side effects of these therapies. Cardiotoxicity is one of the most relevant side effects on the long-term cancer survivors, because of its high social and economic impact. Drug metabolism can result in active metabolites or toxic metabolites that can lead to important side effects. The metabolites of anticancer drugs are possible culprits of cardiotoxicity; however, the cardiotoxicity of many of the metabolites in several drug classes was not yet suitably studied so far. On the other hand, the use of prodrugs that are bioactivated through metabolism can be a good alternative to obtain more cardio safe drugs. In this review, the methods to obtain and study metabolites are summarized and their application to the study of a group of anticancer drugs with acknowledged cardiotoxicity is highlighted. In this group of drugs, doxorubicin (DOX, 1), mitoxantrone (MTX, 2), cyclophosphamide (CTX, 3) and 5-fluorouracil (5-FU, 4) are included, as well as the tyrosine kinase inhibitors, such as imatinib (5), sunitinib (6) and sorafenib (7). Only with the synthesis and purification of considerable amounts of the metabolites can reliable studies be performed, either in vitro or in vivo that allow accurate conclusions regarding the cardiotoxicity of anticancer drug metabolites and then pharmacological prevention or treatment of the cardiac side effects can be done.
Keywords: Anticancer drugs; cardiotoxicity; in vitro models; metabolites; metabolites synthesis.
Similar articles
- The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity.
Reis-Mendes AF, Sousa E, de Lourdes Bastos M, Costa VM. Reis-Mendes AF, et al. Curr Drug Metab. 2015;17(1):75-90. doi: 10.2174/1389200216666151103114926. Curr Drug Metab. 2015. PMID: 26526839 - Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy.
Reis-Mendes A, Gomes AS, Carvalho RA, Carvalho F, Remião F, Pinto M, Bastos ML, Sousa E, Costa VM. Reis-Mendes A, et al. Arch Toxicol. 2017 Apr;91(4):1871-1890. doi: 10.1007/s00204-016-1839-z. Epub 2016 Sep 14. Arch Toxicol. 2017. PMID: 27629428 - Fluoropyrimidine-Induced Cardiotoxicity: Manifestations, Mechanisms, and Management.
Layoun ME, Wickramasinghe CD, Peralta MV, Yang EH. Layoun ME, et al. Curr Oncol Rep. 2016 Jun;18(6):35. doi: 10.1007/s11912-016-0521-1. Curr Oncol Rep. 2016. PMID: 27113369 Review. - Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.
Moudgil R, Yeh ET. Moudgil R, et al. Can J Cardiol. 2016 Jul;32(7):863-870.e5. doi: 10.1016/j.cjca.2016.01.027. Epub 2016 Feb 2. Can J Cardiol. 2016. PMID: 27117975 Free PMC article. Review. - Cardio-oncology Part I: chemotherapy and cardiovascular toxicity.
O'Hare M, Sharma A, Murphy K, Mookadam F, Lee H. O'Hare M, et al. Expert Rev Cardiovasc Ther. 2015 May;13(5):511-8. doi: 10.1586/14779072.2015.1032940. Epub 2015 Apr 5. Expert Rev Cardiovasc Ther. 2015. PMID: 25843285 Review.
Cited by
- Cytoprotective Effects of Dinitrosyl Iron Complexes on Viability of Human Fibroblasts and Cardiomyocytes.
Akentieva NP, Sanina NA, Gizatullin AR, Shkondina NI, Prikhodchenko TR, Shram SI, Zhelev N, Aldoshin SM. Akentieva NP, et al. Front Pharmacol. 2019 Nov 11;10:1277. doi: 10.3389/fphar.2019.01277. eCollection 2019. Front Pharmacol. 2019. PMID: 31780929 Free PMC article. - A proteome-wide systems toxicological approach deciphers the interaction network of chemotherapeutic drugs in the cardiovascular milieu.
Giri S, Manivannan J, Srinivasan B, Sundaresan L, Gajalakshmi P, Chatterjee S. Giri S, et al. RSC Adv. 2018 Jun 4;8(36):20211-20221. doi: 10.1039/c8ra02877j. eCollection 2018 May 30. RSC Adv. 2018. PMID: 35541641 Free PMC article. - Pixantrone, a new anticancer drug with the same old cardiac problems? An in vitro study with differentiated and non-differentiated H9c2 cells.
Reis-Mendes A, Alves M, Carvalho F, Remião F, Bastos ML, Costa VM. Reis-Mendes A, et al. Interdiscip Toxicol. 2018 May;11(1):13-21. doi: 10.2478/intox-2018-0002. Epub 2018 Aug 6. Interdiscip Toxicol. 2018. PMID: 30181708 Free PMC article. - Doxorubicin Is Key for the Cardiotoxicity of FAC (5-Fluorouracil + Adriamycin + Cyclophosphamide) Combination in Differentiated H9c2 Cells.
Pereira-Oliveira M, Reis-Mendes A, Carvalho F, Remião F, Bastos ML, Costa VM. Pereira-Oliveira M, et al. Biomolecules. 2019 Jan 10;9(1):21. doi: 10.3390/biom9010021. Biomolecules. 2019. PMID: 30634681 Free PMC article. - Protective Mechanism of Hydrogen Sulfide against Chemotherapy-Induced Cardiotoxicity.
Du S, Huang Y, Jin H, Wang T. Du S, et al. Front Pharmacol. 2018 Jan 26;9:32. doi: 10.3389/fphar.2018.00032. eCollection 2018. Front Pharmacol. 2018. PMID: 29434549 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources